Pivotal Therapeutics Inc. announced earnings results for the three months ended September 30, 2014. For the quarter, the company reported a loss of CAD 1,632,052 or CAD 0.02 per common share. This included CAD 97,200 in non-cash stock option expenses, CAD 156,145 in interest on long-term debt and CAD 378,018 in accretion expense.